ArticleMediators of inflammation2025
Foxj2 Attenuates LPS-Induced Inflammatory Response in Macrophages.
Article in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Foxj2 Attenuates LPS-Induced Inflammatory Response in Macrophages.Mediators of inflammation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Macrophages are central to innate immune responses and are crucial in maintaining homeostasis and managing inflammatory diseases. Forkhead box J2 (Foxj2) is a member of the forkhead/hepatocyte nuclear factor 3 transcription factor family and is essential for multiple biological functions. However, the involvement of Foxj2 in the inflammatory process in macrophages remains unclear. Objective: The present study aimed to explore the role of Foxj2 in the inflammatory processes of macrophages activated through lipopolysaccharide (LPS) stimulation. Methods: The modulation of Foxj2 expression in macrophages in response to LPS stimulation was investigated via reverse-transcription quantitative (RT-q) PCR, Western blot, and immunofluorescence staining assays. Macrophages were infected with adenovirus vectors to upregulate the expression of the Foxj2 gene. Luciferase reporter gene assay and chromatin immunoprecipitation (ChIP)-PCR analysis were used to determine the regulatory relationship between Foxj2 and Tak1 (transforming growth factor-β-activated kinase 1). Results: LPS stimulation of peritoneal macrophages led to a significant decrease in Foxj2 expression. In addition, LPS treatment led to Foxj2 depletion in several mouse tissues, including the heart, liver, spleen, lungs, kidneys, adipose tissue, blood vessels, and peritoneal macrophages. Furthermore, Foxj2 overexpression ameliorated the mRNA expression of TNF, IL-1β, IL-6, IL-12, IFN-stimulated gene 15, and IFN-β in macrophages treated with LPS. Additionally, Foxj2 overexpression attenuated phosphorylation of Stat1, p65, Erk1/2, Jnk, and p38. Subsequent experiments confirmed the binding of Foxj2 to the promoter region of Tak1, led to the suppression of Tak1's transcriptional activity. Moreover, a reduction in Foxj2 levels was observed during the pathological processes of numerous diseases characterized by inflammation, including high-fat diet (HFD)-induced obesity, HFD-induced nonalcoholic fatty liver disease (NAFLD), doxorubicin-induced cardiomyopathy, acute myocardial infarction (AMI) and D-galactose induced aging conditions. Conclusion: The present findings indicated that Foxj2 is crucial in mitigating macrophage inflammation induced by LPS and might be considered a target for treating sepsis and other inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.